therapeutics

Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes

ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced…

2 months ago

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),…

2 months ago

Starton Therapeutics to Present at Biotech Showcase 2026

Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in…

2 months ago

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key…

2 months ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 12, 2025 16:30 ET  | Source: Zevra Therapeutics CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc.…

2 months ago

Aukera Therapeutics Comes Out of Stealth

BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is…

2 months ago

Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology.HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025…

2 months ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…

2 months ago

TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition

December 06, 2025 17:30 ET  | Source: TScan Therapeutics, Inc. Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23)…

2 months ago

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

2 months ago